{"result": "(\"entity\"<|>CELIAC DISEASE<|>EVENT<|>Celiac disease is an immune-based disorder affecting the small intestine, leading to malabsorption and various nutritional deficiencies.)\n##\n(\"entity\"<|>NUTRITIONAL DEFICIENCIES<|>EVENT<|>Nutritional deficiencies are common in patients with celiac disease due to malabsorption of essential nutrients.)\n##\n(\"entity\"<|>ISOSOURCE STANDARD<|>ORGANIZATION<|>Isosource Standard is a nutritional supplement designed for patients with specific dietary needs, including those with celiac disease.)\n##\n(\"entity\"<|>NUTRISON ESTÁNDAR<|>ORGANIZATION<|>Nutrison Estándar is a nutritional product that can be used by patients requiring dietary adjustments, particularly those with gluten intolerance.)\n##\n(\"entity\"<|>FRESUBIN<|>ORGANIZATION<|>Fresubin is a brand of nutritional supplements that cater to patients with dietary restrictions, including gluten-free options.)\n##\n(\"entity\"<|>EDANEC<|>ORGANIZATION<|>Edanec is a nutritional product that is gluten-free and designed for patients with specific dietary needs.)\n##\n(\"entity\"<|>GLUTEN<|>EVENT<|>Gluten is a protein found in wheat and other grains that can trigger adverse reactions in individuals with celiac disease.)\n##\n(\"entity\"<|>LACTOSE<|>EVENT<|>Lactose is a sugar found in milk that some celiac patients may become intolerant to, especially at the time of diagnosis.)\n##\n(\"entity\"<|>STEROIDS<|>EVENT<|>Steroids are medications used in the treatment of refractory celiac disease to manage symptoms and inflammation.)\n##\n(\"entity\"<|>IMMUNOSUPPRESSORS<|>EVENT<|>Immunosuppressors are drugs that may be used in the treatment of severe cases of celiac disease to reduce immune response.)\n##\n(\"entity\"<|>NUTRITIONAL SUPPORT<|>EVENT<|>Nutritional support refers to the dietary interventions and supplements provided to patients with celiac disease to manage their condition.)\n##\n(\"relationship\"<|>CELIAC DISEASE<|>NUTRITIONAL DEFICIENCIES<|>Celiac disease leads to nutritional deficiencies due to malabsorption of nutrients in the small intestine<|>8)\n##\n(\"relationship\"<|>ISOSOURCE STANDARD<|>NUTRITIONAL SUPPORT<|>Isosource Standard is used as a nutritional support for patients with celiac disease<|>7)\n##\n(\"relationship\"<|>NUTRISON ESTÁNDAR<|>NUTRITIONAL SUPPORT<|>Nutrison Estándar provides nutritional support tailored for patients with dietary restrictions<|>7)\n##\n(\"relationship\"<|>FRESUBIN<|>NUTRITIONAL SUPPORT<|>Fresubin offers nutritional support for patients with specific dietary needs, including gluten-free options<|>7)\n##\n(\"relationship\"<|>EDANEC<|>NUTRITIONAL SUPPORT<|>Edanec is a gluten-free nutritional product used for dietary management in celiac disease<|>7)\n##\n(\"relationship\"<|>GLUTEN<|>CELIAC DISEASE<|>Gluten is the trigger for adverse reactions in individuals diagnosed with celiac disease<|>9)\n##\n(\"relationship\"<|>LACTOSE<|>CELIAC DISEASE<|>Lactose intolerance can occur in patients with celiac disease, especially at diagnosis<|>6)\n##\n(\"relationship\"<|>STEROIDS<|>CELIAC DISEASE<|>Steroids are used to treat severe cases of celiac disease that do not respond to standard treatment<|>8)\n##\n(\"relationship\"<|>IMMUNOSUPPRESSORS<|>CELIAC DISEASE<|>Immunosuppressors may be necessary for managing refractory celiac disease<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ) durante 4-6 semanas y se evalúan los síntomas.\n\nExiste un 30% de pacientes que no responden a la dieta. En este grupo lo más común es la falta de adherencia al tratamiento. Si una historia dietética precisa descarta esta posibilidad deberemos investigar la posibilidad de otros cuadros que causen atrofia vellositaria (como intolerancia a proteínas de leche de vaca, enfermedad de Chron, gastroenteritis eosinofílica, giardiasis, etc.) o también cuadros con clínica gastrointestinal parecida como síndrome de intestino irritable, intolerancia a lactosa o sobrecrecimiento bacteriano25.\n\nOtra posibilidad es la presencia de «esprúe refractario» con progresión del cuadro malabsortivo y riesgo vital importante. Su tratamiento se centra en el uso de esteroides e inmunosupresores. Finalmente, en casos resistentes a esteroides, hay que descartar la presencia de yeyunitis ulcerativa asociada a linfoma26.\n\n## 7. Soporte nutricional artificial\n\nLos pacientes celiacos pueden presentar una intolerancia secundaria a la lactosa, principalmente al diagnóstico de la enfermedad, que suele desaparecer a medida que la mucosa intestinal se recupera. Por tanto, inicialmente es necesario realizar una restricción temporal de la lactosa de la dieta. También suele ser necesario al inicio restringir la grasa y suplementar ciertos micronutrientes (Fe, Ca, ácido fólico y las vitaminas liposolubles). Con este fin, pueden utilizarse temporalmente suplementos nutricionales adaptados a las necesidades específicas de cada paciente (sin gluten y sin lactosa) (Isosource Standard®, Nutrison estándar®, fresubin®, Edanec®, etc.). En situaciones de malnutrición severa con atrofia intestinal muy importante se puede ver comprometida inicialmente la absorción con alimentos naturales por vía oral; en estos casos, podrá recurrirse a fórmulas de nutrición enteral elementales que incluyan triglicéridos de cadena media, oligopéptidos y aminoácidos. Por último, en casos de extrema desnutrición excepcionalmente debe instaurarse nutrición parenteral hasta que se recupere, al menos parcialmente.\n\nEs necesario conocer la composición de los productos de nutrición artificial, al igual que cualquier otro medicamento que utilicen estos pacientes para tener la certeza de que no contiene gluten.\n\n## 8. Resumen y conclusiones\n\nLa enfermedad celiaca es un trastorno de base inmunitaria que afecta al intestino delgado produciendo atrofia de su epitelio absortivo. Es un problema nutricional frecuente (1:85-1:540) que comprende riesgos para la salud a corto y largo plazo. Del consejo nutricional adecuado depende la mayor parte del éxito terapéutico. La dieta sin gluten, que inicialmente puede parecer simple, implica múltiples ajustes en la dieta de forma individualizada y la alerta constante ante la posibilidad de ingesta inadvertida de gluten en la dieta. La información nutricional al respecto es amplia y bien actualizada, a través de las asociaciones de enfermos afectos.\n\nLas líneas de investigación futuras se dirigen hacia la completa identificación de los epítopos exactos que causan la sensibilización al gluten, para así establecer terapias más precisas o desarrollar cereales modificados que no causen sensibilización.\n\n## 9. Bibliografía\n\n1. Barton SH, Kelly DG, Murray JA. Nutritional deficiencies in celiac disease. Gastroenterol Clin North Am. 2007 Mar;36(1):93-108.\n2. American Gastroenterological Association medical position statement: Celiac Sprue. Gastroenterology 2001; 120: 1522-5.\n3. Ciclitira PJ, King AL, Fraser JS. AGA technical review on Celiac Sprue. American Gastroenterological Association. Gastroenterology 2001; 120: 1526-40.\n4. Booth,CC. history of celiac disease. BMJ 1989; 298-527.\n5. Pallav K, Kabbani T, Tariq S, Vanga R, Kelly CP, Leffler DA. Clinical utility of celiac disease-associated HLA testing. Dig Dis Sci. 2014 Sep;59(9):2199-206.\n6. Woodward J. Improving outcomes of refractory celiac disease - current and emerging treatment strategies Clin Exp Gastroenterol. 2016 Aug 3;9:225-36.\n---\nTema 17. Enfermedad celiaca. Dieta controlada en gluten    303\n\n7. Shan, L, Molberg, O, Parrot, I, et al. Structural ba-\n   sis for gluten intolerance in celiac sprue. Science\n   2002; 297:2275.\n8. Fasano A, Sapone A, Zevallos V, Schuppan D.\n   Nonceliac gluten sensitivity. Gastroenterology.\n   2015 May;148(6):1195-204.\n9. Ferguson,\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}